Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 5/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473159 | 0.83 | BRAF (0.44) | BRAF | |
| SCHEMBL4484461 | 0.81 | BRAF (0.40) | BRAFGPBAR1ABL1 | |
| SCHEMBL4479657 | 0.76 | KDM4E (0.36) | KDM4ETEK | |
| SCHEMBL4473800 | 0.76 | KDM4E (0.32) | KDM4E | |
| SCHEMBL4477906 | 0.76 | KDM4E (0.36) | KDM4ETEK | |
| SCHEMBL4469729 | 0.76 | NR2E1 (0.35) | KDM4EABL1NTRK1DDR1NTRK3 | |
| SCHEMBL4482574 | 0.74 | ABL1 (0.39) | KDM4ENR1H4ABL1TEKP4HTM | |
| SCHEMBL4474214 | 0.72 | PSEN1 (0.42) | KDM4E | |
| SCHEMBL4466806 | 0.72 | BRAF (0.41) | BRAF | |
| SCHEMBL4469722 | 0.69 | BRAF (0.42) | BRAFNR1H4ABL1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | claimed |
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL2 | KDM4E 4443/4885RIPK2 1539/4885BRAF 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.